𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

✍ Scribed by Kazuo Nishimura; Norio Nonomura; Yutaka Yasunaga; Natsuki Takaha; Hitoshi Inoue; Hideki Sugao; Seiji Yamaguchi; Osanu Ukimura; Tsuneharu Miki; Akihiko Okuyama

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
90 KB
Volume
89
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of the oral cyclophospham
Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. ChrΓ©tien; Sy πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 413 KB πŸ‘ 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

High-dose calcitriol, zoledronate, and d
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma
✍ Michael J. Morris; Oren Smaletz; David Solit; W. Kevin Kelly; Susan Slovin; Carl πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 97 KB

## Abstract ## BACKGROUND Preclinical and clinical data have suggested that high‐dose calcitriol (1,25‐dihydroxycholecalciferol) has activity against prostate carcinoma. Pulse‐dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulse‐dose